AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16195291
Drug: Various interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various interventions for treatment (35 trials)
Trial: 7674172
Drug: Heparin-surface-modified lens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-surface-modified lens
Trial: 2403065
Drug: Caffeine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (400 mg/d)
Trial: 7223262
Drug: Cefamandole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (3 x 2 g I.V. within 24 hrs, first dose at anesthetic induction)
Trial: 7223262
Drug: Clindamycin-Tobramycin (clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin-Tobramycin (clindamycin 600 mg - tobramycin 80 mg/8 hrs for 24 hrs, first dose at anesthetic induction)
Trial: 31293021
Drug: N. sativa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. sativa (2 g/day)
Trial: 23955585
Drug: Control arms
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arms (standard chemotherapy)
Trial: 23955585
Drug: Experimental arms
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arms (intensified chemotherapy)
Trial: 19446622
Drug: PHFST 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHFST 240 mg single dose
Trial: 19446622
Drug: PHFST 180-210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHFST 180-210 mg single dose
Trial: 19446622
Drug: PHFST 30-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHFST 30-150 mg single dose
Trial: 19446622
Drug: PHFST multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHFST multiple dosing (60 mg b.i.d. up to 120 mg b.i.d.)
Trial: 8562752
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of azithromycin orally (single dose)
Trial: 8562752
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of ceftriaxone im (single dose)
Trial: 24161420
Drug: Accelerated Partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Partial Breast Irradiation (APBI) - 37.5 Gy in 3.75 Gy per fraction delivered twice daily
Trial: 24161420
Drug: Whole Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Breast Irradiation (WBI) - 48 Gy delivered in daily fractions of 2 Gy, with or without additional 10 Gy to the tumor bed
Trial: 19733721
Drug: Naproxcinod 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxcinod 750 mg
Trial: 11741526
Drug: Treatment (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (specific treatment not mentioned)
Trial: 9505912
Drug: Abciximab added
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab added to intravenous heparin and aspirin regimen
Trial: 2543246
Drug: Max‐EPA (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Max‐EPA (3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid)
Trial: 4969551
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg t.d.s.
Trial: 4969551
Drug: Verapamil 40
RxNorm normalized name: verapamil 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 40 mg t.d.s.
Trial: 4969551
Drug: Propranolol 100
RxNorm normalized name: propranolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 100 mg t.d.s.
Trial: 25605841
Drug: Rituximab re-treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab re-treatment (RR)
Trial: 8271292
Drug: Fenretinide 200
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide 200 mg daily for a median of 32 months
Trial: 2929705
Drug: Artificial tear
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tear formulation (solution 15 with demulcent and buffering system, osmolarity 162 mOsm/l)
Trial: 20367667
Drug: 24 mg/mL
RxNorm normalized name: sulfur 24 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg/mL hyaluronic acid with pre-incorporated 0.3% lidocaine
Trial: 18397977
Drug: 6-month thyroid
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month thyroid hormone substitution regimen to obtain euthyroidism
Trial: 9803985
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral tablet dose of 20 mg temocapril hydrochloride
Trial: 9803985
Drug: Seven once
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven once daily oral tablet doses of 20 mg temocapril hydrochloride
Trial: 19846281
Drug: Lorazepam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2.5 mg single dose)
Trial: 15016255
Drug: Written information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written information provided prior to treatment
Trial: 7932194
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day lovastatin
Trial: 2676654
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day lovastatin
Trial: 7932194
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day lovastatin
Trial: 7932194
Drug: 0 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/day lovastatin (baseline)
Trial: 27175685
Drug: Dexmedetomidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.3 μg/kg/hour continuous infusion)
Trial: 20187094
Drug: Intra-arterial (IA)
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial (IA) chemoradiation with 4x150 mg/m(2) cisplatin administered in the tumor-feeding artery on Days 1, 8, 15, 22, followed by sodium thiosulfate and 70 Gy in 35 daily fractions.
Trial: 20187094
Drug: Intravenous chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemoradiation with 3x100 mg/m(2) cisplatin infusion on Days 1, 22, 43 and 70 Gy in 35 daily fractions.
Trial: 20187094
Drug: Intravenous chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemoradiation
Trial: 14529100
Drug: Albuterol 180
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 180 microg
Trial: 3919531
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus glibenclamide, 5 mg twice daily
Trial: 31174713
Drug: Double-blind injectable
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind injectable opioid agonist treatment (iOAT)
Trial: 26884557
Drug: CGA arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CGA arm (treatment allocation based on Comprehensive Geriatric Assessment)
Trial: 26884557
Drug: Standard arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard arm (chemotherapy allocation based on performance status and age)
Trial: 19625343
Drug: Irinotecan (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (70 mg/m²) and Docetaxel (25 mg/m²) administered on days 1 and 8 of each 3-week cycle
Trial: 16353468
Drug: Centric occlusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centric occlusion stabilization oral appliance
Trial: 9809926
Drug: Arotinolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arotinolol (10 mg twice a day)
Trial: 8561267
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (total dose = 550 mg or 9.6 mg/kg)
Trial: 8561267
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous artesunate (total dose = 8.8 mg/kg)
Trial: 2692838
Drug: Long-acting propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting propranolol (LA.P), 160 mg once-daily
Trial: 322152
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (2 and 10 mg)
Trial: 31145281
Drug: 4 SMS
RxNorm normalized name: Somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 SMS per week offering advice, motivation, and information about medication adherence, physical activity, dietary measures, and smoking cessation (if appropriate)
Trial: 27008585
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise (combination of aerobic and resistance protocols, 60 minutes)
Trial: 21288211
Drug: Gabapentin 900
RxNorm normalized name: gabapentin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg pre-incision
Trial: 21288211
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg pre-incision
Trial: 21288211
Drug: Gabapentin 900
RxNorm normalized name: gabapentin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg post-incision
Trial: 21288211
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg post-incision
Trial: 16189334
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg pre-incision
Trial: 16189334
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg post-incision
Trial: 16424410
Drug: All formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All formoterol treatment regimens
Trial: 12819323
Drug: Recommended anti-hypertensive
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended anti-hypertensive therapy
Trial: 8247239
Drug: Dexamethasone in
RxNorm normalized name: Dexamethasone Intensol
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone in high but rapidly decreasing doses
Trial: 2935349
Drug: Metoprolol (1.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (1.25, 1.25, 2.5, and 5.0 mg)
Trial: 31702643
Drug: HT080 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HT080 (500 mg) twice a day for 12 weeks
Trial: 31702643
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day for 12 weeks
Trial: 23192600
Drug: Daily Disturbances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Disturbances factor of PSQI
Trial: 21311402
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (open discectomy)
Trial: 17164728
Drug: Sirolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (10 mg loading dose followed by 3 mg/m²/day, target levels 10-15 ng/mL for 6 months, then 5-10 ng/mL thereafter)
Trial: 17164728
Drug: Cyclosporine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (4 to 8 mg/kg/day, target levels 150-300 ng/mL for 6 months, then 100-200 ng/mL thereafter)
Trial: 9407377
Drug: Saquinavir (SQV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir (SQV, Invirase) treatment
Trial: 8428855
Drug: Theophylline 300
RxNorm normalized name: theophylline 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 300 mg twice a day (R1)
Trial: 8428855
Drug: Salbutamol 4
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 4 mg tid (R2)
Trial: 8428855
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (200/4mg, R3)
Trial: 8428855
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (100/2mg, R4)
Trial: 8428855
Drug: Placebo (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (calcium lactate 300 mg) tid (R5)
Trial: 27098449
Drug: Dietary feedback
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary feedback and weekly text messages
Trial: 22241281
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg risperidone
Trial: 16390852
Drug: Impaired renal
RxNorm normalized name: nut.tx.impaired renal fxn,soy ORAL BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired renal function (estimated glomerular filtration rate <60 ml/min/1.73 m²) in men and women aged 65 years or older
Trial: 16390852
Drug: Cardiovascular drug
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardiovascular drug prescriptions (angiotensin-converting enzyme inhibitors and beta-blockers)
Trial: 10939683
Drug: Scopolamine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (1.5 mg, transdermal patch)
Trial: 10939683
Drug: Cyclizine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclizine (50 mg tablet)
Trial: 19350339
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate treatment
Trial: 22078189
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg twice daily on day 1 plus placebo 1 daily for 4 days
Trial: 22078189
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg twice daily on day 1 plus ethinyl estradiol (EE) 20 mcg daily for days 2-5
Trial: 11477920
Drug: Integrated traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy
Trial: 15074086
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (WM) alone
Trial: 8576842
Drug: Teicoplanin loading
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin loading doses of 6 to 30 mg/kg, followed by once-a-day treatment of approximately the same doses over several weeks.
Trial: 30703258
Drug: BMS-986231 0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986231 0.1, 0.33, 1, 3, 5, 10, and 15 μg/kg/min infused over 24 hours
Trial: 30703258
Drug: BMS-986231 10
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986231 10 μg/kg/min infused over 48 hours
Trial: 26895920
Drug: Protective lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective lung ventilation (low tidal volume of 6 ml/kg with PEEP of 5 cmH2O)
Trial: 26895920
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation with alveolar recruitment maneuver (tidal volume of 10 ml/kg with inspiratory pressure of 40 cmH2O for 30s)
Trial: 15957991
Drug: Temporising treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporising treatment of severe early onset pre-eclampsia
Trial: 1767898
Drug: Continuous lumbar
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous lumbar epidural infusion of morphine
Trial: 1767898
Drug: Continuous lumbar
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous lumbar epidural infusion of fentanyl
Trial: 1767898
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of loratadine
Trial: 7332913
Drug: Elixophyllin SR
RxNorm normalized name: THEOPHYLLINE 125MG CAP,SA (ELIXOPHYLLIN SR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elixophyllin SR capsules
Trial: 25059332
Drug: Oral moisturising
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral moisturising gel containing egg yolk antibodies against Candida albicans (anti‐CA IgY)
Trial: 25059332
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral moisturising gel without anti‐CA IgY
Trial: 22440906
Drug: Biocompatible solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible solution
Trial: 19514864
Drug: losartan 25mg/chlorthalidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 25mg/chlorthalidone 6.25 mg
Trial: 19514864
Drug: losartan 25
RxNorm normalized name: LOSARTAN 25MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 25 mg/hydrochlorothiazide 12.5 mg
Trial: 19514864
Drug: losartan 25mg/chlorthalidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 25mg/chlorthalidone 12.5 mg
Trial: 11985943
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement (50 ml curd containing Lactobacillus acidophilus)
Trial: 11985943
Drug: Isocaloric supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric supplement (control group)
Trial: 7636683
Drug: Packaged rice-based
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Packaged rice-based oral rehydration solution (R-ORS)
Trial: 7636683
Drug: Standard glucose-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glucose-electrolyte oral rehydration solution (G-ORS)
Trial: 367712
Drug: Acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (400 to 800 mg daily)
Trial: 367712
Drug: Methyldopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (500 to 1000 mg daily)
Trial: 31517745
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin administered 12 hours before the operation
Trial: 31517745
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin administered 1 hour before the operation
Trial: 21157403
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sotrastaurin twice daily with standard-exposure tacrolimus (treatment B)
Trial: 21157403
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sotrastaurin twice daily with reduced-exposure tacrolimus (treatment C)
Trial: 21157403
Drug: mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mycophenolic acid (MPA) with standard-exposure tacrolimus (treatment A)
Trial: 17556790
Drug: Isotretinoin (Acutaneï)
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin (Acutaneï) therapy
Trial: 17556790
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or topical acne therapy (control group)
Trial: 37060
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (0.1 and 0.25 mg in 1 ml solution)
Trial: 37060
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (protective application before antigen inhalation)
Trial: 17373090
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/day + aggressive debridement
Trial: 17373090
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/day alone
Trial: 15111485
Drug: Liraglutide (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (6 micro g/kg) administered subcutaneously once daily
Trial: 11813932
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% twice daily (treatment-naive)
Trial: 11813932
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% once daily (treatment-naive)
Trial: 11813932
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% twice daily (previously treated)
Trial: 11813932
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% once daily (previously treated)